SCHEMBL19457367

SCHEMBL19457367

Cc1cccc(S(=O)(=O)N2CC[C@H](O)C2)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.55
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
ALDH1A1 P00352 7/20 0.50
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 1/20 0.47
PAX8 Q06710 3/20 0.47
GRM5 P41594 1/20 0.46
KDM4E B2RXH2 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19457361 1.00 EPHX2 (0.55) EPHX2KMT2AMEN1ALDH1A1JAK2
SCHEMBL19457363 0.92 EPHX2 (0.53) EPHX2KMT2AMEN1ALDH1A1GAA
SCHEMBL19457359 0.92 EPHX2 (0.53) EPHX2KMT2AMEN1ALDH1A1GAA
SCHEMBL19457360 0.91 EPHX2 (0.60) EPHX2KMT2AMEN1ALDH1A1GAA
SCHEMBL12111692 0.86 EPHX2 (0.52) EPHX2KMT2AMEN1ALDH1A1JAK2
SCHEMBL17861034 0.83 MBTD1 (0.61) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL17843469 0.83 MBTD1 (0.61) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL17860988 0.83 MBTD1 (0.61) KMT2AMEN1ALDH1A1LMNANPSR1
SCHEMBL2856989 0.83 PKLR (0.57) ALDH1A1LMNANPSR1
SCHEMBL20885016 0.82 KCNH2 (0.47) KMT2AALDH1A1LMNAKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3440084-B1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS DANA FARBER CANCER INST INC (US) 2022-12-21 EP disclosed
WO-2017177092-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-10-12 WO disclosed